RayKnowChina Research Map
Shortlist

Guangzhou

Guangdong Provincial Hospital of Chinese Medicine

广东省中医院

Listed for 22 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Guangdong Provincial Hospital of Chinese Medicine

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led
  2. Hepatocellular carcinoma肝细胞癌25 papers led
  3. Stomach cancer胃癌12 papers led
  4. Lung cancer肺癌41 papers led
  5. Pancreatic cancer胰腺癌6 papers led
  6. Breast cancer乳腺癌50 papers led1 open trial led
  7. Glioma胶质瘤12 papers led
  8. Osteosarcoma骨肉瘤2 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  10. Neuroblastoma神经母细胞瘤3 papers led
  11. Ewing sarcoma尤文肉瘤1 paper led
  12. Beta thalassaemiaβ 地中海贫血0 papers led
  13. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病4 papers led
  14. Myasthenia gravis重症肌无力0 papers led
  15. Coronary heart disease冠心病15 papers led
  16. Congenital heart disease先天性心脏病7 papers led
  17. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  19. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  20. Amyotrophic lateral sclerosis肌萎缩侧索硬化症4 papers led
  21. IgA nephropathyIgA 肾病6 papers led
  22. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led

Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Takayasu arteritis, Hepatic echinococcosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 332025

24 hospitals in Guangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AI
Departments in papersRadiation oncologyNeurosurgeryENT / head & neck surgery
Papers it led5
  1. Clinical Study of Tuhuanglian Liquid Wet Compress on Acute Radiation Dermatitis of Nasopharyngeal Carcinoma.2025Critical reviews in biomedical engineeringRCT
  2. Therapeutic association and mechanistic exploration of modified Sijunzi Decoction in radiation-induced sinusitis: an integrated retrospective analysis and network pharmacology study.2025European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  3. Efficient T staging in nasopharyngeal carcinoma via deep Learning-Based Multi-Modal classification.2025European journal of radiology
  4. Survival analysis of a comprehensive treatment strategy for internal carotid artery blowout syndrome by nasopharyngeal carcinoma.2023Head & neck
  5. Prognostic generalization of multi-level CT-dose fusion dosiomics from primary tumor and lymph node in nasopharyngeal carcinoma.2023Medical physics
All its trials on ClinicalTrials.gov, any status1
  1. A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine RegimensStatus unknownNCT01762514Study sitePhase 2Start 2013-01
More papers found outside PubMed (not counted)4
  1. ASO Visual Abstract: Endoscopic Transoropharyngeal Retropharyngeal Lymph Node (RPLN) Dissection for RPLN Recurrence Nasopharyngeal Carcinoma2025Annals of Surgical Oncologyarticle
  2. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figsharedataset
  3. PD-1 Combined with VEGF/VEGFR2 Inhibitors for the Re-Treatment of Metastatic Nasopharyngeal Carcinoma2023Journal of Biomedical Nanotechnologyarticle
  4. Survival Follow-Up Analysis of EBBA Treatment Strategy for Internal Carotid Artery Invasion by Nasopharyngeal Carcinoma2022SSRN Electronic Journalpreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 25 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
25
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 3320232024: 111120242025: 552025

15 hospitals in Guangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  2. Recruiting
    Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
    Phase
    Not given
    Started
    2023-11
    Posted
    Registry
    NCT06157060

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 3 listed hospitals as study sitesGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging, AI & early detectionLocal treatment (ablation, TACE, HAIC)Immunotherapy & targeted drugs
Departments in papersPathology / laboratory medicineMedical oncologyGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led25
  1. Triptolide impacts CSF1R expression and reprograms the suppressive function of myeloid-derived suppressor cells via targeting the ER stress pathway.2026Cytokine
  2. Identification and validation of an explainable machine learning model for hepatocellular carcinoma at high risk: a retrospective multicenter cohort study.2026International journal of surgery (London, England)Free full text
  3. Simultaneous versus sequential transcatheter arterial chemoembolization combined with microwave ablation for hepatocellular carcinoma: A retrospective propensity score-matched analysis.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  4. Molecular subtyping and therapeutic prediction of hepatocellular carcinoma based on exosome proteomics.2025International journal of biological macromolecules
  5. Nano-pectic polysaccharide from vinegar-baked Radix Bupleuri enhances methotrexate efficacy against hepatocellular carcinoma via BCRP and MRP2 downregulation.2025International journal of biological macromolecules
  6. The combination of serum lncRNA PTTG3P and mRNA PTTG1 serves as a diagnostic and prognostic marker for hepatocellular carcinoma.2025Molecular medicine reportsFree full text
  7. Decoding the possible mechanism of action of Paeoniflorigenone in combating Aflatoxin B1-induced liver cancer: an investigation using network pharmacology and bioinformatics analysis.2025Toxicology mechanisms and methods
  8. Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122+CXCR3+PD-1- memory T cells.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells.2024Cancer immunology research
  10. Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning.2024European radiologyFree full text
  11. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.2024Frontiers in immunologyFree full text
  12. Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma.2024Frontiers of medicine
  13. Comparison of structure and the synergistic anti-hepatocellular carcinoma effect of three polysaccharides from vinegar-baked Radix Bupleuri.2024International journal of biological macromolecules
  14. Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  15. Multiparametric MRI based deep learning model for prediction of early recurrence of hepatocellular carcinoma after SR following TACE.2024Journal of cancer research and clinical oncologyFree full text
  16. Rapid evaluation of hepatocellular carcinoma by detecting plasma exosomes with time-resolved fluorescence immunochromatographic test strips.2024Mikrochimica acta
  17. Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study.2024Scientific reportsFree full text
  18. Tanshinone IIA modulates cancer cell morphology and movement via Rho GTPases-mediated actin cytoskeleton remodeling.2024Toxicology and applied pharmacology
  19. The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials.2023Journal of ethnopharmacology
  20. Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractFree full text
  21. Shentao Ruangan formula promotes apoptosis via the E2F2-p53 pathway in hepatocellular carcinoma.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. Crosstalk of LncRNA HOTAIR and SP1-mediated repression of PDK1 contributes to β-Elemene-inhibited proliferation of hepatocellular carcinoma cells.2022Journal of ethnopharmacology
  23. Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway.2022Molecular carcinogenesisFree full text
  24. MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma.2021European journal of pharmacology
  25. Identification of metabolism genes related to hepatocarcinogenesis and progression in type 2 diabetes mellitus via co-expression networks analysis.2021HereditasFree full text
Chinese-language papers (not in the count)1
  1. [Efficacy and safety of transcatheter arterial chemoembolization followed by hepatic arterial infusion chemotherapy combined with TKI and PD-1 inhibitors as first-line treatment for advanced hepatocellular carcinoma].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  2. Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNARecruitingNCT06157060Study siteStart 2023-11
  3. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)CompletedNCT04000737Study sitePhase 2Start 2020-01

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 12 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
12
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 4420232024: 2220242025: 112025

15 hospitals in Guangzhou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  2. Not yet recruiting
    Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07098949

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryChemotherapy & combined treatmentNutrition & recovery
Departments in papersMedical oncologyGastroenterology / hepatologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led12
  1. Yiqi Huayu Jiedu formula inhibits JAK2/STAT3-mediated partial EMT in treating chronic atrophic gastritis.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  2. Feasibility and value of modular splenic hilar lymphadenectomy technique in laparoscopic total gastrectomy: a retrospective-controlled research.2024Surgical endoscopy
  3. Transthoracic single-port-assisted laparoscopic gastrectomy versus laparoscopic transhiatal approach for Siewert type II adenocarcinoma of the esophagogastric junction: a single-center retrospective study.2024Surgical endoscopy
  4. Electro-acupuncture for health-related quality of life and symptoms in patients with gastric cancer undergoing adjuvant chemotherapy (EAGER): a protocol for a multicenter randomized controlled trial.2023Health and quality of life outcomesFree full text
  5. Risk factors for surgical site infection in patients with gastric cancer: A meta-analysis.2023International wound journalFree full text
  6. Hand-sewn esophagojejunostomy in transthoracic single-port assisted laparoscopic esophagogastrectomy for Siewert type II adenocarcinoma of the esophagogastric junction with esophageal invasion > 3 cm.2023Surgical endoscopy
  7. Quantitative parameters in novel spectral computed tomography: Assessment of Ki-67 expression in patients with gastric adenocarcinoma.2023World journal of gastroenterologyFree full text
  8. Transthoracic Single-Port Assisted Laparoscopic Five-Step Maneuver Lower Mediastinal Lymphadenectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction.2022Annals of surgical oncology
  9. Whether the infracardiac bursa protect right pleura during laparoscopic radical operation of Siewert type II adenocarcinoma of esophagogastric junction?2022BMC cancerFree full text
  10. Diet and gastric cancer risk: an umbrella review of systematic reviews and meta-analyses of prospective cohort studies.2022Journal of cancer research and clinical oncologyFree full text
  11. Acupuncture for Quality of Life in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy.2022Journal of pain and symptom managementRCTFree full text
  12. Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL‑6/JAK/STAT3‑mediated PD‑L1 activity.2021International journal of molecular medicineFree full text
Chinese-language papers (not in the count)5
  1. [A retrospective study on an innovative modular surgical technique in laparoscopic total gastrectomy combined with spleen-preserving hilar lymphadenectomy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Gastric hamartomatous inverted polyps: a clinicopathological analysis of five cases].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [A case report of gastric adenocarcinoma of fundic gland type as suspected gastric neuroendocrine tumor].2022Zhonghua nei ke za zhi
  4. [Safety and feasibility of intrathoracic modified overlap esophagojejunostomy in laparoscopic radical resection of Siewert type Ⅱ adenocarcinoma of esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Safety and feasibility of laparoscopic double-flap technique in digestive tract reconstruction after proximal gastrectomy for esophagogastric junction tumors larger than 5 cm].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status16
  1. FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal MetastasisStatus unknownNCT04886193Lead sponsorN/AStart 2021-04
  2. Laparoscopic Total Gastrectomy With Versus Without BursectomyStatus unknownNCT03117283Lead sponsorPhase 2Start 2017-03
  3. Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal MetastatisStatus unknownNCT03604614Lead sponsorPhase 2Start 2017-06
  4. Laparoscopic Bursectomy and D2 Lymphadenectomy vs.Laparoscopic D2 Lymphadenectomy in Advanced Gastric CancerStatus unknownNCT02969148Lead sponsorN/AStart 2016-11
  5. Laparoscopic-assisted Total Gastrectomy Versus Open Total Gastrectomy With Splenic Hilum Lymph Nodes DissectionStatus unknownNCT02711033Lead sponsorPhase 2Start 2015-10
  6. Acupuncture Combined With Chemotherapy for Gastric Cancer After SurgeryNot yet recruitingNCT07098949Study siteN/AStart 2025-08
  7. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  8. Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home ScenariosCompletedNCT06848400Study siteN/AStart 2025-04
  9. Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer TrialStatus unknownNCT04744649Study sitePhase 2Start 2021-03
  10. Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant ChemotherapyCompletedNCT04360577Study siteN/AStart 2020-05
  11. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  12. Effect of Acupuncture for QoL in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy: a Pilot StudyCompletedNCT03753399Study siteN/AStart 2019-01
  13. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Study sitePhase 2Start 2016-09
  14. Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.WithdrawnNCT02736552Study sitePhase 3Start 2016-03
  15. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)CompletedNCT02745509Study siteN/AStart 2016-03
  16. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 41 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
41
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 7720212022: 6620222023: 7720232024: 7720242025: 11112025

17 hospitals in Guangzhou for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Electro-Acupuncture in Lung cancER : EALER Study
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07337096

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou

  2. Recruiting
    Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07348965

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  3. Recruiting
    Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07709585

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  4. Recruiting
    Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
    Phase
    N/A
    Started
    2022-06
    Posted
    Registry
    NCT05378334

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  5. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  6. Not yet recruiting
    A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07338396

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Guangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyClinical trials / research unitPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led41
  1. Exploring the mechanisms of Hu-gu-xiao-ji formula and its components for treatment on non-small cell lung cancer using UPLC-QTOF-MS/MS, network pharmacology, and experiments.2026Journal of ethnopharmacology
  2. Fuzheng Kang'ai Formula suppresses NSCLC by inducing a functional crosstalk between autophagy and ferroptosis via EZH2/DOT1L/H3K79me2 signaling.2026Phytomedicine : international journal of phytotherapy and phytopharmacology
  3. Ginsenoside F3 alleviates T cell exhaustion via RIPOR2-mediated immunometabolic reprogramming to potentiate anti-PD-1 therapy.2026Phytomedicine : international journal of phytotherapy and phytopharmacology
  4. Design, synthesis, and biological evaluation of Osimertinib-Cy7 (OSA-Cy7) conjugate as potential theranostic agent targeting activating EGFR mutations.2025BMC biotechnologyFree full text
  5. Bevacizumab-associated glomerular microangiopathy: a case report and literature review.2025BMC nephrologyFree full text
  6. Risk factors for brain metastasis in lung cancer: an umbrella review of systematic reviews and meta-analyses.2025BMJ openFree full text
  7. Polyphyllin I induces ferritinophagy dependent ferroptosis through EZH2 and promotes anti-tumor immunity.2025Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms.2025Clinical epigeneticsFree full text
  9. Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports.2025Frontiers in immunologyFree full text
  10. Serum taurine affects lung cancer progression by regulating tumor immune escape mediated by the immune microenvironment.2025Journal of advanced researchFree full text
  11. Xiaoji decoction induces apoptosis in lung cancer cells and M1 Macrophage polarization via the JAK1/STAT3/PD-L1 pathway.2025Journal of ethnopharmacology
  12. Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway.2025Naunyn-Schmiedeberg's archives of pharmacology
  13. Hu-gu-xiao-ji formula reprograms macrophage polarization and suppresses tumor growth to improve non-small cell lung cancer with bone metastasis via multiple signaling pathways.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  14. Acupuncture reduced incidence of insomnia symptoms in patients with lung cancer: a retrospective cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  15. Unraveling impact and potential mechanisms of baseline pain on efficacy of immunotherapy in lung cancer patients: a retrospective and bioinformatic analysis.2024Frontiers in immunologyFree full text
  16. Complete Response of Locally Advanced Lung Adenocarcinoma Following Basil Combined With Cisplatin Plus Pemetrexed Chemotherapy: A Case Report.2024Integrative cancer therapiesFree full text
  17. Efficacy and Safety of Huachansu as an Adjuvant Therapy for Non-Small Cell Lung Cancer: An Overview of Systematic Reviews and Meta-Analyses.2024Integrative cancer therapies
  18. Integrated microbiome and metabolome analysis reveals synergistic efficacy of basil polysaccharide and gefitinib in lung cancer through modulation of gut microbiota and fecal metabolites.2024International journal of biological macromolecules
  19. Exploring the Mechanism of Ferroptosis Induction by Sappanone A in Cancer: Insights into the Mitochondrial Dysfunction Mediated by NRF2/xCT/GPX4 Axis.2024International journal of biological sciencesFree full text
  20. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.2024Journal of ethnopharmacology
  21. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.2023BMC cancerFree full text
  23. SOX2-associated signaling pathways regulate biological phenotypes of cancers.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  24. Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer.2023Carcinogenesis
  25. The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review.2023International immunopharmacology
  26. Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy.2023Nature communicationsFree full text
  27. Kaempferol promotes non-small cell lung cancer cell autophagy via restricting Met pathway.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  28. Sinomenine hydrochloride bidirectionally inhibits progression of tumor and autoimmune diseases by regulating AMPK pathway.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  29. Lung cancer organoids, a promising model still with long way to go.2022Critical reviews in oncology/hematology
  30. Dissecting the ferroptosis-related prognostic biomarker and immune microenvironment of driver gene-negative lung cancer.2022Experimental biology and medicine (Maywood, N.J.)Free full text
  31. Renal Metastasis from Squamous Cell Carcinoma of the Lung.2022Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  32. Fuzheng Kang' ai decoction inhibits cell proliferation, migration and invasion by modulating mir-21-5p/human phosphatase and tensin homology deleted on chromosome ten in lung cancer cells.2022Journal of traditional Chinese medicine = Chung i tsa chih ying wen panFree full text
  33. Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer.2022Lung cancer (Amsterdam, Netherlands)
  34. Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer.2022Pharmacological research
  35. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.2021BMC cancerFree full text
  36. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.2021Cancer medicineFree full text
  37. Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.2021Clinical lung cancer
  38. Periodontal disease and the risk of prostate cancer: a meta-analysis of cohort studies.2021International braz j urol : official journal of the Brazilian Society of UrologyFree full text
  39. Combined Metabolomics with Transcriptomics Reveals Important Serum Biomarkers Correlated with Lung Cancer Proliferation through a Calcium Signaling Pathway.2021Journal of proteome research
  40. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.2021Journal of the National Comprehensive Cancer Network : JNCCN
  41. Apoptotic activities of brusatol in human non-small cell lung cancer cells: Involvement of ROS-mediated mitochondrial-dependent pathway and inhibition of Nrf2-mediated antioxidant response.2021Toxicology
Chinese-language papers (not in the count)1
  1. [Solasonine promotes apoptosis of non-small cell lung cancer cells by regulating the Bcl-2/Bax/caspase-3 pathway].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status10
  1. Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLCStatus unknownNCT05027100Lead (inferred)N/AStart 2021-09
  2. Electro-Acupuncture in Lung cancER : EALER StudyRecruitingNCT07337096Study siteN/AStart 2026-01
  3. A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer PatientsNot yet recruitingNCT07338396Study siteStart 2026-01
  4. Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal MetastasisRecruitingNCT07348965Study siteN/AStart 2026-03
  5. Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC PatientsRecruitingNCT07709585Study sitePhase 2Start 2026-11
  6. Efficacy and Safety of HGXJT in Bone Metastatic NSCLC PatientsRecruitingNCT05378334Study siteN/AStart 2022-06
  7. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Study sitePhase 1/Phase 2Start 2021-09
  8. Acupuncture for Enhancing Immunotherapy in Advanced NSCLC:a Pilot StudyActive, not recruitingNCT06461338Study siteN/AStart 2024-08
  9. Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKIStatus unknownNCT06277674Study sitePhase 2Start 2023-11
  10. Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.Status unknownNCT04722406Study siteStart 2019-08

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 6 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 112025

13 hospitals in Guangzhou for pancreatic cancer192 hospitals in China for pancreatic cancer

No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 50 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
50
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 6620212022: 3320222023: 111120232024: 101020242025: 17172025

17 hospitals in Guangzhou for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07352137

    Age 18 years to 70 years; women only (registered criteria)

    Led by Guangdong Provincial Hospital of Chinese MedicineGuangzhou

  2. Recruiting
    Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
    Phase
    Not given
    Started
    2022-10
    Posted
    Registry
    NCT06551220

    Age 18 years to 80 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai

  3. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncologyClinical trials / research unitPathology / laboratory medicine
Papers it led50
  1. Effect of HER2-Low Expression on the Efficacy of CDK4/6 Inhibitors in Breast Cancer: A Meta-Analysis.2026Clinical breast cancer
  2. Target validation and drug discovery for TNBC: Targeting the Lin28B/Let-7/PBK with the ponicidin.2026European journal of medicinal chemistry
  3. Xiaoyao San reverses the pro-breast cancer effect of depression by inhibiting glutamate levels in intestinal flora.2026Journal of ethnopharmacology
  4. Ultrasound-Based Deep Learning Radiomics Nomogram for Tumor and Axillary Lymph Node Status Prediction After Neoadjuvant Chemotherapy.2025Academic radiology
  5. The risk of dementia in breast cancer survivors: a meta-analysis of observational studies.2025Annals of medicineFree full text
  6. Prediction of intraductal cancer microinfiltration based on the hierarchical fusion of peri-tumor imaging histology and dual view deep learning.2025BMC cancerFree full text
  7. Machine learning algorithms predict breast cancer incidence risk: a data-driven retrospective study based on biochemical biomarkers.2025BMC cancerFree full text
  8. Molecular mechanisms of bone metastasis in breast cancer based on transcriptomic and microbiomic analysis.2025Cancer causes & control : CCCFree full text
  9. Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients.2025Cancer reports (Hoboken, N.J.)Free full text
  10. Role of low-density cholesterol and Interleukin-17 interaction in breast cancer pathogenesis and treatment.2025Cell biology international
  11. Small protein ERSP encoded by LINC02870 promotes triple negative breast cancer progression via IRE1α/XBP1s activation.2025Cell death and differentiationFree full text
  12. Effect of Huaier granule on prognosis of breast cancer: A single-center propensity score matching retrospective study.2025Chinese medical journalFree full text
  13. Extra-skeletal Ewing's sarcoma with EWSR1::ERG translocation of the breast: a case report.2025Diagnostic pathologyFree full text
  14. Ultrasound-based radiomic nomogram for predicting the invasive status of breast cancer: a multicenter study.2025European journal of medical researchFree full text
  15. BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer.2025Frontiers in immunologyFree full text
  16. Atractylodes macrocephala Koidz. Polysaccharide Alleviates Chemotherapy-Induced Depression-Like Behaviors Through the Gut-Brain Axis.2025International journal of molecular sciencesFree full text
  17. Liquiritin in Aiduqing formula inhibits breast cancer neoangiogenesis by suppressing CTSK-mediated lysosomal degradation of CXCL1 in tumor-associated macrophages.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  18. The chemosensitizing activity of betulinic acid in suppressing macrophage polarization through GSK-3β/β-catenin/CXCL1 signaling in breast cancer.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  19. Predicting the axillary lymph node tumor burden in breast cancer patients using ultrasonic radiomics nomogram model.2025PloS oneFree full text
  20. Intraoperative ultrasound-guided wire(IOUS-wire) localization biopsy versus preoperative fine needle aspiration cytology(FNAC) for early breast cancer with clinically positive nodes, a retrospective cohort study.2025World journal of surgical oncologyFree full text
  21. Clinical and radiological evaluation of a phyllodes tumor of the breast: a case report.2024Anti-cancer drugs
  22. Tanshinone I improves TNBC chemosensitivity by suppressing late-phase autophagy through AKT/p38 MAPK signaling pathway.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  23. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.2024British journal of cancerFree full text
  24. Tumor-associated macrophages/C-X-C motif chemokine ligand 1 promotes breast cancer autophagy-mediated chemoresistance via IGF1R/STAT3/HMGB1 signaling.2024Cell death & diseaseFree full text
  25. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.2024Journal of experimental & clinical cancer research : CRFree full text
  26. Baohuoside I chemosensitises breast cancer to paclitaxel by suppressing extracellular vesicle/CXCL1 signal released from apoptotic cells.2024Journal of extracellular vesiclesFree full text
  27. Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism.2024Journal of nanobiotechnologyFree full text
  28. Female patients with hepatitis B may exhibit a reduced risk of breast cancer: A review of NHANES data.2024MedicineFree full text
  29. XIAOPI formula inhibits chemoresistance and metastasis of triple-negative breast cancer by suppressing extracellular vesicle/CXCL1-induced TAM/PD-L1 signaling.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  30. The mediating effect of perceived social support between family resilience and meaning in life in breast cancer patients.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  31. ASO Author Reflections: A More Effective Radiotherapy Modality for Early Breast Cancer: Intraoperative Radiotherapy as a Tumour Bed Boost Combined with Whole Breast Irradiation.2023Annals of surgical oncology
  32. Intraoperative Radiotherapy as a Tumour-Bed Boost Combined with Whole Breast Irradiation Versus Conventional Radiotherapy in Patients with Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.2023Annals of surgical oncologyFree full text
  33. Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  34. Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway.2023Cancer letters
  35. Cefoselis enhances breast cancer chemosensitivity by directly targeting GRP78/LRP5 signalling of cancer stem cells.2023Clinical and translational medicineFree full text
  36. 10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling.2023Drug design, development and therapyFree full text
  37. A Delphi Study of Expert Consensus on Chinese Medicine Syndrome Differentiation and Herbal Use for Early Breast Cancer.2023Integrative cancer therapiesFree full text
  38. Naringenin in Si-Ni-San formula inhibits chronic psychological stress-induced breast cancer growth and metastasis by modulating estrogen metabolism through FXR/EST pathway.2023Journal of advanced researchFree full text
  39. An Unsupervised Learning-Based Regional Deformable Model for Automated Multi-Organ Contour Propagation.2023Journal of digital imagingFree full text
  40. Chronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM/CXCL1 signaling.2023Journal of experimental & clinical cancer research : CRFree full text
  41. A novel incision technique of a totally implanted venous access port in the upper arm for patients with breast cancer.2023World journal of surgical oncologyFree full text
  42. Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patients.2022Annals of palliative medicine
  43. 1H-NMR based metabolic study of MMTV-PyMT mice along with pathological progress to screen biomarkers for the early diagnosis of breast cancer.2022Molecular omics
  44. Crosstalk between Depression and Breast Cancer via Hepatic Epoxide Metabolism: A Central Comorbidity Mechanism.2022Molecules (Basel, Switzerland)Free full text
  45. Cross-platform genomic identification and clinical validation of breast cancer diagnostic biomarkers.2021AgingFree full text
  46. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.2021Cancer medicineFree full text
  47. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.2021Cell communication and signaling : CCSFree full text
  48. Chinese Medicine Syndromes and Stages of Early Breast Cancer: Hierarchical Cluster Analysis and Implication for Clinical Practice.2021Journal of alternative and complementary medicine (New York, N.Y.)
  49. The Effectiveness of Tai Chi in Patients With Breast Cancer: An Overview of Systematic Reviews and Meta-Analyses.2021Journal of pain and symptom management
  50. Aiduqing formula suppresses breast cancer metastasis via inhibiting CXCL1-mediated autophagy.2021Phytomedicine : international journal of phytotherapy and phytopharmacology
Chinese-language papers (not in the count)2
  1. [Kaixinsan alleviates adriamycin-induced depression-like behaviors in mice by reducing ferroptosis in the prefrontal cortex].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [Mechanism of Kaixin Powder in alleviating breast cancer chemotherapy-induced cognitive impairment by transcriptome association analysis].2024Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
All its trials on ClinicalTrials.gov, any status6
  1. Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary IncisionEnrolling by invitationNCT07352137Lead sponsorN/AStart 2026-01
  2. Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression PatternsRecruitingNCT06551220Study siteStart 2022-10
  3. Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerRecruitingNCT04790305Study sitePhase 4Start 2021-06
  4. Patterns of Breast Cancer Management and Prognosis of Breast Cancer in ChinaStatus unknownNCT04076111Study siteStart 2019-09
  5. Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast CancerStatus unknownNCT01642771Study sitePhase 3Start 2012-06
  6. Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer PatientsStatus unknownNCT01503905Study siteN/AStart 2011-12

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 12 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.2%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 2220222023: 2220232024: 0020242025: 222025

13 hospitals in Guangzhou for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine
Papers it led12
  1. LRP5 enhances glioma cell proliferation by modulating the MAPK/p53/cdc2 pathway.2025International journal of medical sciencesFree full text
  2. MRI-based habitat radiomics for preoperatively predicting IDH status in gliomas.2025Neurosurgical focus
  3. A review of traditional Chinese medicine Curcumae Rhizoma for treatment of glioma.2023International review of neurobiology
  4. An overview of Twist1 in glioma progression and recurrence.2023International review of neurobiology
  5. Radiomic Analysis of Contrast-Enhanced MRI Predicts DNA Copy-Number Subtype and Outcome in Lower-Grade Gliomas.2022Academic radiology
  6. A novel model based on necroptosis-related genes for predicting immune status and prognosis in glioma.2022Frontiers in immunologyFree full text
  7. Lower-Grade Gliomas: Predicting DNA Methylation Subtyping and its Consequences on Survival with MR Features.2021Academic radiology
  8. Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.2021Cancer scienceFree full text
  9. Development of MR-based preoperative nomograms predicting DNA copy number subtype in lower grade gliomas with prognostic implication.2021European radiology
  10. Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.2021Progress in brain research
  11. Multimodal imaging in the differential diagnosis of glioma recurrence from treatment-related effects: A protocol for systematic review and network meta-analysis.2021Progress in brain research
  12. Network pharmacological mechanism of Cinobufotalin against glioma.2021Progress in brain research

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

30 hospitals in Guangzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

12 hospitals in Guangzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

22 hospitals in Guangzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Guangzhou for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

18 hospitals in Guangzhou for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 4 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisAcute attack treatmentBiologic drugs
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led no English-language PubMed papers on myasthenia gravis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Guangzhou for myasthenia gravis89 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 15 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.3%.

Papers led
15
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 3320232024: 2220242025: 332025

10 hospitals in Guangzhou for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07803471

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhengzhou

  2. Not yet recruiting
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    Phase
    N/A
    Started
    2021-09
    Posted
    Registry
    NCT04995159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatrics
Papers it led15
  1. Causal association between lipoproteins and risk of coronary artery disease-a systematic review and meta-analysis of Mendelian randomization studies.2026Clinical research in cardiology : official journal of the German Cardiac Society
  2. Causality between Cholecystectomy, Blood Lipids, and Major Adverse Cardiac and Cerebrovascular Events: A Multimodal Approach Highlighting Lipid Regulation.2025Bulletin of experimental biology and medicine
  3. Comprehensive Analysis Based on Genes Associated With Cuproptosis, Ferroptosis, and Pyroptosis for the Prediction of Diagnosis and Therapies in Coronary Artery Disease.2025Cardiovascular therapeuticsFree full text
  4. Causal effects between gut microbiota and coronary heart disease: A Mendelian randomization study.2025MedicineFree full text
  5. Giant right coronary artery aneurysm with right coronary artery-right atrial fistula.2024Coronary artery disease
  6. Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanism of Qushi Huatan Decoction Against Coronary Heart Disease.2024Drug design, development and therapyFree full text
  7. Development and Validation of Prediction Models for All-Cause Mortality and Cardiovascular Mortality in Patients on Hemodialysis: A Retrospective Cohort Study in China.2023Clinical interventions in agingFree full text
  8. Cardiovascular involvement in Epstein-Barr virus infection.2023Frontiers in immunologyFree full text
  9. Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis.2023Journal of interventional cardiologyFree full text
  10. Ferritinophagy in vascular endothelial cells regulated by nanoparticles may benefit the prevention of atherosclerosis and in-stent restenosis.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  11. Correlation between Characteristics of Coronary Plaque and Chinese Medicine Syndromes of Coronary Heart Disease: A Cross-Sectional Study Analysed by Intravascular Ultrasound.2022Chinese journal of integrative medicine
  12. CALM1 rs3179089 polymorphism might contribute to coronary artery disease susceptibility in Chinese male: a case-control study.2022Genes & genomics
  13. Application value of Qisexingtai hand diagnostic method in diagnosis of coronary artery disease.2022Journal of traditional Chinese medicine = Chung i tsa chih ying wen panFree full text
  14. Effect of Tongguan Capsules () on Restenosis after Coronary Stent Implantation: Study Protocol for A Randomized Controlled Trial.2021Chinese journal of integrative medicine
  15. Chemical profile and potential mechanisms of Huo-Tan-Chu-Shi decoction in the treatment of coronary heart disease by UHPLC-Q/TOF-MS in combination with network pharmacology analysis and experimental verification.2021Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Chinese-language papers (not in the count)1
  1. [Platelet-to-lymphocyte ratio as a biomarker for predicting coronary artery lesions in Chinese children with Kawasaki disease: a Meta analysis].2023Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
All its trials on ClinicalTrials.gov, any status4
  1. The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease PatientsStatus unknownNCT02850627Lead sponsorPhase 4Start 2016-07
  2. Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart DiseaseNot yet recruitingNCT07803471Study siteN/AStart 2026-09
  3. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS SystemNot yet recruitingNCT04995159Study siteN/AStart 2021-09
  4. Syndrome Differentiation in the Management of Chronic Stable Coronary Artery Disease (SCAD) to Improve QualityStatus unknownNCT03018769Study siteStart 2016-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 7 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 2220232024: 0020242025: 112025

12 hospitals in Guangzhou for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

12 hospitals in Guangzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR AntibodiesNot yet recruitingNCT07858175Study siteStart 2026-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

20 hospitals in Guangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Guangzhou for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 4 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 112025

13 hospitals in Guangzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 6 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.8%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 1120232024: 0020242025: 112025

16 hospitals in Guangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led6
  1. Moderate to severe chronic arteriolar lesions is an independent risk factor for adverse renal outcomes in IgA nephropathy.2025PloS oneFree full text
  2. Nomogram for the prediction of crescent formation in IgA nephropathy patients: a retrospective study.2023BMC nephrologyFree full text
  3. The role of urine IgG in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis.2022International urology and nephrology
  4. Prediction of prognosis in immunoglobulin a nephropathy patients with focal crescent by machine learning.2022PloS oneFree full text
  5. Comparison between outcomes of IgA nephropathy with nephrotic-range proteinuria and nephrotic syndrome: do podocytes play a role?2022Renal failureFree full text
  6. Volume of Crescents Affects Prognosis of IgA Nephropathy in Patients without Obvious Chronic Renal Pathology.2021American journal of nephrology
Earlier papers (2016–2020)4
  1. MicroRNA-27a-3p directly targets FosB to regulate cell proliferation, apoptosis, and inflammation responses in immunoglobulin a nephropathy.2020Biochemical and biophysical research communications
  2. Small RNA deep sequencing reveals novel miRNAs in peripheral blood mononuclear cells from patients with IgA nephropathy.2020Molecular medicine reports
  3. Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review.2016BMC pulmonary medicine
  4. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.2016Nephrology (Carlton, Vic.)
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

9 hospitals in Guangzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

广东省中医院

Guangdong Provincial Hospital of Chinese Medicine

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Guangdong Provincial Hospital of Traditional Chinese Medicine; Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Traditional Chinese Medicine (W.W; Guangdong Provincial Hospital of Traditional Chinese Medicine (GPHTCM); Second Clinical College of Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine (Hainan Hospital); GDHCM; Guangdong Hospital of Traditional Chinese Medicine

Suggest a correctionDownload the data